Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc.
19 avr. 2021 08h00 HE
|
Oncocyte Corporation
Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing, both from a standard blood sample Oncocyte’s technologies may provide more precision to the...
Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors
14 avr. 2021 09h02 HE
|
Oncocyte Corporation
IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™
10 avr. 2021 13h31 HE
|
Oncocyte Corporation
Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional...
Oncocyte to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
06 avr. 2021 16h05 HE
|
Oncocyte Corporation
IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte Provides Corporate Update and Reports Fourth Quarter and Annual 2020 Financial Results
16 mars 2021 16h01 HE
|
Oncocyte Corporation
DetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020 On track to launch DetermaIO™ in 2021 for immune therapy selection ...
Oncocyte Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO™ to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types
16 mars 2021 08h00 HE
|
Oncocyte Corporation
Novel immuno-oncology algorithm may offer independent and incremental predictive value over current standard biomarkers in the clinic Data suggest that measuring the tumor microenvironment (TME) as a...
Oncocyte To Present New Data at 2021 American Association for Cancer Research (AACR) Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™
15 mars 2021 08h00 HE
|
Oncocyte Corporation
-Results achieved in metastatic bladder cancer suggests Oncocyte’s DetermaIO test may be a strong predictor of Immune Checkpoint Inhibitor (ICI) therapy response in a third cancer type in addition to...
Oncocyte Announces Formation of Medical Advisory Board
09 mars 2021 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte Announces Agreement with MultiPlan Network, Expanding Patient Access to DetermaRx™
04 mars 2021 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...
Oncocyte to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 16
03 mars 2021 16h01 HE
|
Oncocyte Corporation
IRVINE, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...